Cytosorbents Cor (CTSO)

Sudden, temporary vision loss is easy to dismiss, especially when it resolves quickly. But as a new article from NovaVision, the vision rehabilitation division of Vycor Medical, explains, it can be one of the earliest warning signs of an approaching stroke. A transient ischemic attack, or TIA, often produces brief vision changes, including dimming or complete loss of sight in one eye, that can signal something more serious ahead. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. The article explores how sudden vision changes can serve as early stroke warnings, what types of vision loss commonly follow a stroke, and what rehabilitation options are available. As the article notes: “If you experience sudden vision loss, whether in one eye or across part of your visual field, along with any other stroke-associated symptoms, seek medical attention immediately. Acting fast is the single most important thing you can do to reduce the impact of a stroke.” Read the full article here: https://novavision.com/vision-loss-as-a-warning-sign-of-stroke/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$CTSO -Buy Lows

$CTSO companies pay Zacks Small Cap Research (SCR) for research coverage, typically paying between $10,000 and $50,000 annually. This service provides independent research reports, investor relations, and other services for small- and micro-cap firms.

$CTSO On Friday, CTSO closed at an all time low, once again dipping below the share price at which Phil Chan made his last open market purchase. Tell me, what actions if any, would you want to see the Board of Directors take before you’d be willing to increase your CTSO holdings?

$CTSO “stuffing the channel “ to meet quarterly revenue targets could be risk? In the end of year audit such should be flushed out?

Vision changes after a stroke can develop gradually and go unnoticed during recovery. Vycor’s NovaVision division provides a free online visual field screening tool that help stroke survivors check for potential changes and support informed conversations with their healthcare providers. Vycor Medical, Inc. (OTCQB: $VYCO) is a B2i Digital Featured Company. See the company’s complete profile at https://b2idigital.com/vycor-medical. In a new blog post, Vycor discusses five practical reasons online screening can be valuable, including accessibility and convenience, as well as early awareness of issues. As the article notes: “Screening results give you concrete information to discuss with your healthcare team. Rather than describing vague concerns about your vision, you can share screening results that show specific patterns.” Read the entire article here: https://novavision.com/five-reasons-to-consider-online-visual-field-screening/ Vycor operates two divisions: Vycor Medical (ViewSite Brain Access System™ for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke and brain injury patients). The company is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance. More information is available at https://vycormedical.com/investors/. For investor inquiries, please contact [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $CTSO, $SNWV, $IHI

$CTSO: CytoSorbents Price Target Increased to $5.00 Based on Higher Than Expected Gross Margins https://buff.ly/8xeFDUu

$CTSO 09:00 on Jan. 12 2026 What Analysts Are Saying About CytoSorbents Stock #tradeideas

$CTSO 07:25 on Jan. 12 2026 CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75% #tradeideas

$CTSO RSI: 47.53, MACD: -0.0206 Vol: 0.04, MA20: 0.68, MA50: 0.72 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.